EUCTR2006-005860-14-IT进行中（未招募）不适用
A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - ND
EWRON PHARMACEUTICALS0 个研究点目标入组 600 人开始时间: 2009年3月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients are male or female, age 30-80 years, inclusive. If female, they must be either post-menopausal for at least 12 months, surgically sterilized or have undergone hysterectomy. Patients older than 80 years, who meet all other entry criteria, will be considered for enrollment, with approval of the Newron Medical Expert. 2. Patients must have a diagnosis of idiopathic Parkinson?s disease of more than 5 years duration; the diagnosis should be based on medical history and neurological examination. Patients with a duration of Parkinson?s disease of at least 3 years, who meet all other entry criteria, will be considered for enrollment, with approval of the CRO Medical Monitor. 3. Patients must have a Hoehn and Yahr stage of I-IV during an ?off? phase. 4. Patients should be levodopa responsive and must have been receiving treatment with a stable dose of levodopa [4-10 doses per day of any levodopa preparation (including CR, IR or a combination of CR/IR), plus benserazide/carbidopa; with or without addition of a COMT inhibitor] and may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic at the screening visit. Patients will receive the study medication as add-on therapy starting at baseline. 5. Patients should have motor fluctuations, with >1.5 hours ?off? time during the day. 6. Patients must be able to maintain an accurate and complete diary (18-hour), with the help of a caregiver, recording ?on? time, ?on ? time with minor dyskinesia, ?on ? time with troublesome dyskinesia, ?off? time, and time asleep. 7. Patients must be able to understand and willing to sign an approved Informed Consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The patient has any indication of forms of parkinsonism other than idiopathic Parkinson?s disease. 2. If female, the patient is of childbearing potential, pregnant or lactating. 3. The patient is in a late stage of Parkinson?s disease, and is experiencing severe, disabling peak-dose or biphasic dyskinesia and/or unpredictable or widely swinging fluctuations in their symptoms. 4. The patient has a current diagnosis of substance abuse (DSM-IV) or history of alcohol or drug abuse in the past 3 months. 5. The patient has a current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including acute gastric ulcer, hypertension that is not well-controlled, asthma, chronic obstructive pulmonary disease, and Type I diabetes. Patients with a history of gastric ulcer who have not had an episode of acute gastritis in the last 6 months and are not currently experiencing gastric pain will be eligible for inclusion. 6. The patient has second- or third-degree atrio-ventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or a significant ECG abnormality, including QTc >=450 msec (males) or >=470 msec (females), where QTc is based on Bazett?s correction method. 7. The patient has participated in a previous clinical trial with safinamide. 8. The patient has a concomitant disease likely to interfere with the study medication (e.g. capable of altering absorption, metabolism or elimination of the study drug). 9. The patient has a history of psychosis, either previously or currently, or a score >=3 on Item 2 (thought disorder) or 3 (depression) of the UPDRS Section I. 10. The patient has evidence of dementia or cognitive dysfunction, as indicated by a MMSE score < 22, or a score >= 3 on item 1 (mentation) of the UPDRS, Section I. 11. The patient is depressed, as indicated by a GRID-HAMD (17-item scale) score > 17. 12. The patient has a history of allergic response to anticonvulsants, levodopa, or other anti-parkinsonian agents. 13. The patient has a mental or physical condition which would preclude performing efficacy or safety assessments. 14. The patient has hypersenstivity or contraindications to MAO B inhibitors. 15. The patient has a current history of severe dizziness or fainting on standing, due to postural hypotension. 16. The patient has a neoplastic disorder, which is either currently active or has been in remission for less than one year. 17. The patient has had stereotactic surgery as a treatment for his/her Parkinson?s disease. 18. The patient has participated in a previous clinical trial within 30 days of entry into the study (screening visit)or has received treatment with any investigational compound within 30 days or 5 half-lives, whichever is longer, prior to screening. The use of an investigational drug other than safinamide during the study is not permitted.19. The patient is receiving treatment of his/her depression with a MAO inhibitor, a tricyclic, or an SNRI at the screening visit. Note: Use of SSRIs will be permitted, provided the dose is kept as low as possible and remains stable throughout the trial. 20. The patient is receiving treatment of his/her parkinsonian symptoms with a MAO inhibitor. Note: Patients receiving amantadine, COMT inhibitors, DA agonists and/or anticholinergics will be eligible to enter the trial, p
研究者
相似试验
进行中（未招募）
1 期
A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist.Early idiopathic Parkinson’s diseaseMedDRA version: 7.0Level: LLTClassification code 10013113EUCTR2004-000833-12-ESewron Pharmaceuticals S.p.A.
进行中（未招募）
不适用
A Phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonistMedDRA version: 6.1Level: PTClassification code 10061536Parkinson's DiseaseEUCTR2004-000833-12-ITEWRON PHARMACEUTICALS
进行中（未招募）
不适用
A phase III, duble blinded, placebo controlled study of manteinance Pemetrexed plus Best Supportive Care Immediately following induction treatment for advance non-small cell lung cancer.EUCTR2004-002425-52-ITELI LILLY660
招募中
1 期
A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the usual treatments do not workPolyneuropathy, Inflammatory Demyelinating, ChronicMedDRA version: 20.0Level: LLTClassification code: 10077384Term: Chronic inflammatory demyelinating polyneuropathy Class: 10029205CTIS2023-506503-26-00Sanofi-Aventis Research & Development194
进行中（未招募）
1 期
A Clinical Trial Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed Acute Myeloid LeukemiaFMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2015-004856-24-GBDaiichi Sankyo, Inc.536